Ying Jiang - Scotch Plains NJ, US Fang Liang Zhang - Fanwood NJ, US Nicholas J. Murgolo - Millington NJ, US Lin Luo - Edison NJ, US Jason S. Simon - Westfield NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
G01N 33/566
US Classification:
435 721, 435 72, 436501
Abstract:
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
Ying Jiang - Scotch Plains NJ, US Fang Liang Zhang - Fanwood NJ, US Nicholas J. Murgolo - Millington NJ, US Lin Luo - Edison NJ, US Jason S. Simon - Westfield NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
G01N 33/566 C07K 14/705
US Classification:
435 721, 435 71, 435 72, 436501
Abstract:
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
Antibodies And Functional Fragments Thereof That Specifically Bind An Rf-Amide Peptide Or A Precursor Thereof
Ying Jiang - Scotch Plains NJ, US Fang Liang Zhang - Fanwood NJ, US Nicholas J. Murgolo - Millington NJ, US Lin Luo - Edison NJ, US Jason S. Simon - Westfield NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07K 16/00 C12P 21/08
US Classification:
5303879, 5303881, 53038815, 4241391
Abstract:
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
Paul Mathews - Irvington-on-Hudson NY, US Ralph Nixon - Tarrytown NY, US Stephen Schmidt - Nutley NJ, US Ying Jiang - Valhalla NY, US
International Classification:
G01N033/53 G01N033/567
US Classification:
435/007200
Abstract:
The present invention describes cell-based screening methods that allow for the elimination of false-positive results due to nonspecific toxicity of test compounds, while detecting those compounds that specifically modulate cellular metabolites in metabolic pathways associated with diseases and disorders, with particular regard to Alzheimer's disease. The methods are particularly suited to high-throughput screening techniques to identify compounds (drugs) that are effective in a cell-based system. The methods of the invention involve determining within a cell system the levels of both a metabolic precursor and a metabolite of interest and have broad application in high-throughput drug discovery and identification, particularly for precursor and metabolite molecules which are associated with disease and disease progression, such as Alzheimer's disease.